Analyst Price Targets — PGR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 1:18 pm | Paul Newsome | Piper Sandler | $259.00 | $212.80 | StreetInsider | Piper Sandler on Progressive Corp. (PGR): 'One of the Best Insurers at Historically Low Valuation' |
| February 23, 2026 6:34 pm | Alex Scott | Goldman Sachs | $225.00 | $203.69 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Progressive Corp. (PGR) |
| February 23, 2026 2:02 pm | Brian Meredith | UBS | $218.00 | $203.63 | TheFly | Progressive price target lowered to $218 from $226 at UBS |
| February 19, 2026 1:18 pm | — | Evercore ISI | $230.00 | $203.52 | TheFly | Progressive price target lowered to $230 from $237 at Evercore ISI |
| February 19, 2026 1:12 pm | — | Roth Capital | $235.00 | $203.32 | TheFly | Progressive price target lowered to $235 from $260 at Roth Capital |
| February 19, 2026 11:31 am | — | Wells Fargo | $214.00 | $203.28 | TheFly | Progressive price target lowered to $214 from $220 at Wells Fargo |
| February 11, 2026 5:05 pm | — | Jefferies | $216.00 | $209.29 | TheFly | Progressive price target lowered to $216 from $230 at Jefferies |
| February 2, 2026 11:26 am | — | UBS | $226.00 | $208.00 | TheFly | Progressive price target lowered to $226 from $234 at UBS |
| January 29, 2026 1:20 pm | — | BMO Capital | $232.00 | $208.89 | TheFly | Progressive price target lowered to $232 from $239 at BMO Capital |
| January 16, 2026 2:50 pm | — | HSBC | $224.00 | $201.97 | TheFly | Progressive downgraded to Hold from Buy at HSBC |
Latest News for PGR
Net Premiums Written: Increased by almost $9 billion in 2025.Policies in Force: Grew by almost 3.7 million additional policies in 2025.Market Share: Increased
The Progressive Corporation (PGR) Q4 2025 Earnings Call Transcript
The 4-Factor Dividend Growth Portfolio, a rules-based alternative to SCHD, targets high-quality, growth-oriented dividend stocks using four equally weighted metrics. Since inception, the strategy has delivered a 14.17% annualized return, maintaining a 2.12% annualized outperformance over SCHD despite recent SCHD momentum. The portfolio emphasizes strong free cash flow, robust dividend growth, high return on invested…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful and statistically significant results. The study demonstrated that fenebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, markedly reduced the…
Billionaire Investor Ole Andreas Halvorsen worked for Julian Robertson's Tiger Management in the 1990s as the director of equities. Several research analysts from Tiger Management, including Halvorsen, went on to launch successful funds.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.